Abstract : In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02363651
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, February 18, 2020 - 10:32:49 AM Last modification on : Thursday, January 14, 2021 - 11:22:52 AM Long-term archiving on: : Tuesday, May 19, 2020 - 1:20:47 PM
Ioana A Cristea, Florian Naudet. US Food and Drug Administration approval of esketamine and brexanolone. The Lancet. Psychiatry, Elsevier, 2019, 6 (12), pp.975-977. ⟨10.1016/S2215-0366(19)30292-5⟩. ⟨hal-02363651⟩